Entero Therapeutics Inc（ENTO）财务数据ENTOEntero Therapeutics Inc

Evaluating the bottom line, Entero Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1106.61%, provide a clear picture of how effectively ENTO converts its operational activities into shareholder value.

In the context of the broader market, ENTO competes directly with industry leaders such as SNSE and CLDI. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ENTO's gross margin of N/A stands against SNSE's N/A and CLDI's N/A. Such benchmarking helps identify whether Entero Therapeutics Inc is trading at a premium or discount relative to its financial performance.